Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

[1]  G. Morgan,et al.  Guidelines for the diagnosis and management of multiple myeloma 2011 , 2011, British journal of haematology.

[2]  D. Esseltine,et al.  Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma , 2011, European journal of haematology.

[3]  P. Clézardin.  Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. , 2011, Bone.

[4]  G. Morgan,et al.  First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial , 2010, The Lancet.

[5]  G. Morgan,et al.  Defining Myeloma Patients at High Risk of Developing Bone Disease While on Bisphosphonate Treatment , 2010 .

[6]  F. Zhan,et al.  Bone Mineral Density Changes In Patients with Paraproteinemia After Treatment with Bortezomib , 2010 .

[7]  I. Reid,et al.  Characterization of and risk factors for the acute-phase response after zoledronic acid. , 2010, The Journal of clinical endocrinology and metabolism.

[8]  M. Dimopoulos,et al.  Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Robert A Kyle,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. , 2009, Mayo Clinic proceedings.

[10]  R. Kyle,et al.  Treatment of multiple myeloma: a comprehensive review. , 2009, Clinical lymphoma & myeloma.

[11]  M. Dimopoulos,et al.  The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Zangari,et al.  The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo , 2009, American journal of hematology.

[13]  M. Dimopoulos,et al.  Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Somerfield,et al.  American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Eriksen,et al.  Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006. , 2007, Critical reviews in oncology/hematology.

[16]  P. L. Bergsagel,et al.  Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. , 2006, Mayo Clinic proceedings.

[17]  J. Berenson.  Myeloma bone disease. , 2005, Best practice & research. Clinical haematology.

[18]  D. Esseltine,et al.  Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma , 2005, British journal of haematology.

[19]  Y. Ohashi,et al.  Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Jonathan R. Green.  Bisphosphonates: preclinical review. , 2004, The oncologist.

[21]  R. Coleman.  Bisphosphonates: clinical experience. , 2004, The oncologist.

[22]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[23]  A. Howell,et al.  Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma , 2003, Cancer.

[24]  B. Hillner,et al.  American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Glatt,et al.  Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). , 2002, Journal of medicinal chemistry.

[26]  R J Cook,et al.  Analysis of repeated events , 2002, Statistical methods in medical research.

[27]  A. Howell,et al.  Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. , 2001, Cancer journal.

[28]  R. Coleman.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.

[29]  J. Kanis,et al.  Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myeloma , 2001, British journal of haematology.

[30]  Dunn,et al.  A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma , 1998, British journal of haematology.

[31]  R. Bell,et al.  Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Gill,et al.  Cox's regression model for counting processes: a large sample study : (preprint) , 1982 .

[33]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.